MBX BIOSCIENCES INC. - COMMON STOCK

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

07 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference

18 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism

02 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

18 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

07 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

MBX Biosciences to Participate in Upcoming November Investor Conferences

28 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

30 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

16 Sep 2024 16:05:00 By Nasdaq GlobeNewswire